Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 30 years executive experience including Abbott and JNJ and has been involved three successful start-ups. He has a B.S, from Penn State University and an MBA from... More
My company:
Raygent Capital
My blog:
raygent.com
  • Rayno Biopharmaceutical Stocks Q1 2014 Performance 0 comments
    Apr 1, 2014 5:52 PM | about stocks: ABBV, ARIA, GILD

    Rayno Biopharmaceutical Portfolio 3/31/14

    Most of our biotech picks did well in a tough quarter that went through a severe correction in early February and again in late March. Many small and mid-cap momentum stocks were crushed but indices (FBT,IBB) overall held the early February technical levels. Use the two ETFs and FBIOX for re-balancing portfolios.

    Our top winners for the first quarter were :

    Albany Molecular (NASDAQ:AMRI) up 81%!, Alexion (NASDAQ:ALXN) up 14.3%, Seattle Genetics (NASDAQ:SGEN) up 11.6%, and Alkermes (NASDAQ:ALKS) up 10.2%.

    The top losers were:

    Pharmacyclics (NASDAQ:PCYC) down 5.7%, Gilead Sciences (NASDAQ:GILD) down 5.5% and Vertex (NASDAQ:VRTX) down 4.9%.

    We added three new stocks: Abbvie (NYSE:ABBV) an Abbott spin-off large cap biotech, Ariad (ARIA a small cap biotech and ROCHE Holdings (OTCQX:RHHBY) a leading large cap drug and diagnostic Company. We also recommended increasing the cash position to 20% early in the corrective phase. Keep in mind that most biotech stocks were up about 60% in 2013.

    Biotech stocks are now in a two day rally moving many stocks up 5%. We will review our diagnostic and tools portfolio later this week.

    Rayno Biopharmaceutical Picks

    2014   Original P Price Price Price % Ret Price % Ret  
    Summary Ticker Recomm   Apr'11 Dec'12 Nov'13 11/1/13 3/31/14 YTD  
                         
    Abbvie ABBV 3/25/14 51.7 new       51.4 0  
    Achillion ACHN 3/4/13 8.6 new   2.53 -68 3.3 -1.5  
    Alexion ALXN 2/2/09 35 100.8 95.4 123.4 2.26 153.13 14.3  
    Alkermes ALKS 3/22/13 23 new 18.5 35.6 59.29 44.09 10.2  
    Albany Mol AMRI 2/10/11 4.68 4.32 5.3 13.2 140.7 18.59 81  
    Ariad ARIA 3/25/14 7.61 new       8.06 5.9  
    Astex ASTX* 12/27/11 1.63   2.7 8.5 49.48 acq    
    Amgen AMGN 2/2/09 55 54 87.4 118.7 13.1 123.34 8  
    Biogen BIIB 2/2/09 48.5 73.25 149 243 48.85 305.87 9.4  
    Cephalon CEPH* 2/2/09 76.5 76.92 80.18   30 acq    
    Cubist CBST 2/2/09 21.5 28.35 42.4 61.9 19.2 73.15 6.3  
    FT Arca ETF FBT 4/15/10 37.5 41.3 46 64.6 29.6 76.7 11  
    Gilead GILD 2/2/09 51 42.8 72.7(s) 71 40.67 70.86 -5.5  
    iShares ETF IBB 2/2/09 70.5 101.1 137.8 206 29.9 236.3 3.8  
    Fido Biotech FBIOX             194.85 7.22  
    ImmunoGen IMGN 12/22/11 12.4   12.5 16.3 34.8 14.93 1.9  
    Optimer OPTR* 2/18/11 11.8 13.8 9.2 12.8 60 acq    
    Pharmacycl PCYC 6/8/12 38.2   58 122 47.8 100.22 -5.7  
    Regeneron REGN 2/2/09 17.5 45.43 173 286 34.5 300.28 9.1  
    Roche ADR RHHBY 1/30/14 67 new       37.75(s) 7.7  
    Seattle Gen. SGEN 2/2/09 9.5 15.72 23.3 39 41 45.56 11.6  
    Vertex VRTX 11/15/13 62.8 new       70.65 -4.9  
    ViroPharma VPHM* 2/2/09 12 20.05 22.9 39 29.4 acq    
                         
    *acquired                    

    Chart forFirst Trust NYSE Arca Biotech Index (NYSEARCA:<a href='http://seekingalpha.com/symbol/FBT' title='First Trust NYSE Arca Biotechnology Index ETF'>FBT</a>)

    Disclosure: I am long ABBV, ARIA, GILD, ACHN.

    Additional disclosure: Long FBIOX.

    Stocks: ABBV, ARIA, GILD
Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.